Bioclinica, ArisGlobal partner to 'transform drug safety model'

Tablets production

Bioclinica has teamed up with ArisGlobal and its safety cloud platform to help the CRO run its drug safety monitoring services.

In a statement, the Newtown, PA-based CRO said that a “top 20 pharmaceutical company” has already selected Bioclinica to standardize its safety case processing service on the ArisGlobal platform, while two other companies are said to be making the switch from competing platforms.

Under this partnership, Bioclinica also becomes the preferred partner for Fort Lauderdale, FL-based ArisGlobal in business process consulting and change management as sponsors implement or upgrade its drug safety software, ARISg. 

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

“Early adoption speaks to the strength and value of our joint solution in addressing industry’s long-wanted desire for such a safety offering,” said Bioclinica's president of eHealth solutions, Mukhtar Ahmed.

ArisGlobal’s VP of safety George Philips added: “Through our partnership with Bioclinica, we are able to provide the pharmaceutical industry with an unprecedented level of streamlined and cost efficient end-to-end pharmacovigilance services. By utilizing these services, resources within an organization can now be shifted to address other pressing needs.”

ArisGlobal and Bioclinica’s Safety and Regulatory Solutions division (formerly known as Synowledge) said the deal was made in order to “deliver cost-effective and regulatory compliant services.”

Ahmed added that: “The formation of this partnership addresses the full continuum of pharmacovigilance as a service. Together Bioclinica and ArisGlobal provide the most comprehensive solution, whether an organization wants to handle safety internally or outsource it to our team of safety experts.”

Bioclinica has signed a number of deals in the past 18 months, including most recently a new tie-up with Japanese CRO EPS to focus on risk-based monitoring in clinical trials--one of 6 new deals and pacts the company has made since 2014.  

In February, it also launched a new internal “Post-Approval Research” division as it looks to take big steps into the growing realm of helping biopharma with data and costs after launch.

- check out the release

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.